Novartis AG Sponsored ADR's pharmaceutical (NVS.US) groundbreaking self-immunity drugs have been filed for listing in China.
Noven Pharmaceuticals' Eliumab antibody (ianalumab) has been submitted for approval for market in China.
On February 6th, the CDE website showed that Novartis AG Sponsored ADR Pharmaceuticals (NVS.US) has filed for market approval of ianalumab in China. ianalumab is a fully human monoclonal antibody targeting the B lymphocyte activating factor receptor (BAFF-R) acquired by Novartis AG Sponsored ADR through the acquisition of MorphoSys. It has a dual mechanism of action of depleting B cells and inhibiting BAFF-R, and can be used to treat various autoimmune diseases such as Sjgren's syndrome, immune thrombocytopenia (ITP), systemic lupus erythematosus (SLE), among others. This drug is the first anti-BAFF-R antibody to complete Phase III studies.
Related Articles
EVEREST MED (01952) Weishiping has been approved by the National Medical Products Administration to be launched, opening a new era of oral treatment for moderate to severe ulcerative colitis.
Toyota Motor Corp. Sponsored ADR (TM.US) raised its full-year profit guidance. CFO Kenichiro Ito will take over as CEO.
HK Stock Market Move | WESTCHINACEMENT (02233) falls by nearly 10% again, planning to issue 300 million US dollars of preferred notes to repurchase 2026 notes.
EVEREST MED (01952) Weishiping has been approved by the National Medical Products Administration to be launched, opening a new era of oral treatment for moderate to severe ulcerative colitis.
Toyota Motor Corp. Sponsored ADR (TM.US) raised its full-year profit guidance. CFO Kenichiro Ito will take over as CEO.
HK Stock Market Move | WESTCHINACEMENT (02233) falls by nearly 10% again, planning to issue 300 million US dollars of preferred notes to repurchase 2026 notes.
